NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00405756,A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.,https://clinicaltrials.gov/study/NCT00405756,,COMPLETED,The purpose of this study is to determine whether lenalidomide is safe and effective in the treatment of patients with newly diagnosed Multiple Myeloma who are 65 years of age or older.,YES,Newly Diagnosed Multiple Myeloma,DRUG: Lenalidomide: Double-blind Induction|DRUG: Melphalan|DRUG: Prednisone|DRUG: Aspirin|DRUG: Placebo|DRUG: Lenalidomide: Double-blind Maintenance|DRUG: Lenalidomide: Open-label,"Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC), Data as of 11 May 2010 cutoff. PFS was calculated as the time from randomization to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria.

PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia., up to 165 weeks","Kaplan Meier Estimates of Progression-free Survival (PFS) From Start of Maintenance Therapy Period Based on the Response Assessment by the Central Adjudication Committee (CAC), Data as of 11 May 2010 cutoff. PFS calculated from the start of the Maintenance period to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause.

PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria.

PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia., Approximately week 37 (start of cycle 10) to week 165|Kaplan Meier Estimates of Overall Survival (OS), Data as of 11 May 2010 cutoff. Overall survival (OS) was defined as the time between randomization and death. Participants who died, regardless of the cause of death, were considered to have had an event. Participants who were lost to follow-up prior to the end of the trial, or who were withdrawn from the trial, were censored at the time of last contact. Participants who were still being treated were censored at the last available date available, or clinical cut-off date, if it was earlier., up to 177 weeks|Kaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC), Data as of 11 May 2010 cutoff. TTP was the time between randomization and disease progression as determined by the CAC. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria.

PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia., up to 165 weeks|Number of Participants in Disease Response Categories Representing Their Best Response During the Double-blind Treatment Period, Data as of 11 May 2010 cutoff. Best response was determined by the Central Assessment Committee (CAC) based on the European Group for Blood and Marrow Transplantation (EBMT) criteria: Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of bone lesions, plus other factors); Partial Response (PR)-not all CR criteria, plus \>=50% reduction in serum monoclonal paraprotein plus others; Stable Disease (SD)- not PR or PD; Progressive Disease (PD)- reappearance of monoclonal paraprotein, bone lesions, other; Not Evaluable (NE)., Up to 165 weeks|Time to First Response, Data as of 11 May 2010 cutoff. Time to first response was defined as the time from start of treatment until first response as assessed by the Central Assessment Committee (CMC) based on European Group for Blood and Marrow Transplantation (EBMT) criteria., Up to 66 weeks|Kaplan Meier Estimates for Duration of Response as Determined by the Central Adjudication Committee (CAC), Data as of 11 May 2010 cutoff. Duration of myeloma response was defined as the time from the initial response date to the earlier of progressive disease (PD) as determined by the CAC or death on study. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria.

PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia., Up to 149 weeks|Kaplan Meier Estimates for Time to Next Antimyeloma Therapy, Data as of 11 May 2010 cutoff. Time to the next antimyeloma therapy was defined as time from randomization to the start of another non-protocol antimyeloma therapy. Participants who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy., Up to 168 weeks|Summary of Participants With Treatment-Emergent Adverse Events (TEAE) During the Double-Blind Treatment Period, Data as of 11 May 2010 cutoff. Participant counts in different categories of TEAEs during the double-blind treatment period. A TEAE is as any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. Dose reduction includes reduction with or without interruption., Up to 169 weeks (Double-blind therapy period plus 4 weeks)|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale, Data as of 11 May 2010 cutoff. EORTC QLC-C30 is a 30-item questionnaire to assess the quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Physical Functioning Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of role functioning., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Emotional Functioning Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of emotional functioning., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Congitive Functioning Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of cognitive functioning., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Social Functioning Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of social functioning., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the fatigue scale = higher level of symptomatology/problems., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Nausea and Vomiting Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the nausea/vomiting scale = higher level of symptomatology/problems., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the pain scale = higher level of symptomatology/problems., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Dyspnoea Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the dyspnoea scale = higher level of symptomatology/problems., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Insomnia Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the insomnia scale = higher level of symptomatology/problems., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Appetite Loss Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the appetite loss scale = higher level of symptomatology/problems., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Constipation Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the constipation scale = higher level of symptomatology/problems., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Diarrhoea Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the diarrhea scale = higher level of symptomatology/problems., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Financial Difficulties Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a problem scale like the financial problems scale = higher level of financial problems., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Side Effects of Treatment Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the side effects scale = higher level of symptomatology., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Future Perspective Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future., Baseline (Day 0), Months 4, 7, 10, 13, 16|Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Body Image Scale, Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the body image scale, higher scores = better body image., Baseline (Day 0), Months 4, 7, 10, 13, 16",,Celgene Corporation,,ALL,OLDER_ADULT,PHASE3,459,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",CC-5013-MM-015|2006-001865-41,2007-01,2009-11,2016-04,2006-11-30,2012-05-11,2017-01-11,"Hematology Oncology Clinics of Australia, Level 5, Mater Medical Centre, South Brisbane, Queensland, 4101, Australia|Royal Adelaide Hospital Institute of Medical and Veterinary Science, Adelaide, South Australia, 5000, Australia|Royal Prince Alfred Hospital, Camperdown, 2050, Australia|Peter MacCallum Cancer Centre Divsion of Haematology Medical Oncology, East Melbourne, 3006, Australia|Frankston Hospital, Frankston, 3199, Australia|The Alfred Hospital, Melbourne, 3141, Australia|Sir Charles Gairdner Hospital, Nedlands, 6009, Australia|Princess Alexandra Hospital, Woolloongabba, 4102, Australia|University Hospital Innsbruck, Innsbruck, 6020, Austria|University Hospital of Salzburg St Johanns Spital, Salzburg, 5020, Austria|Medical University of Vienna, Vienna, 1090, Austria|Wilhelminenspital, Vienna, 1160, Austria|Medical University of Vienna, Vienna, A-1090, Austria|Republican Scientific and Practical Centre of Radiation Medicine and Human Ecology, Gomel, 246 042, Belarus|City Clinical Hospital 9, Minsk, 220116, Belarus|AZ St-Jan Brugge Oostende AV, Brugge, 8000, Belgium|AZ-VUB, Brussels, 1090, Belgium|UZ Gasthuisberg, Leuven, 3000, Belgium|Centre Hospitalier Universitaire de Liege, Liege, 4000, Belgium|Fakultni nemocnice Brno, Brno, 625 00, Czech Republic|Fakultni nemocnice Hradec Kralove, Hradec Kralove, 500 05, Czech Republic|Fakultni Nemocnice Olomouc, Olomouc, 77520, Czech Republic|Vseobecna Fakultni Nemocnice v Praze, Prague, 128 081, Czech Republic|Hæmatologisk afd. B Aalborg Sygehus Syd, Aalborg, 9000, Denmark|Medicinsk afd. Vejle Sygehus, Vejle, 7100, Denmark|CHU, Caen, 14033, France|CH - Hôpital Dupuytren, Limoges Cedex 1, 87042, France|CHU Montpellier- Hopital Lapeyronie, Montpellier Cedex 5, 34295, France|Assistance Publique - Hôpitaux de Paris AP-HP, Paris, 75475, France|CHU Purpan, Toulouse cedex 9, TSA 40031-31059, France|Ltd M.Zodelava Hematology Centre, Tbilisi, 0112, Georgia|Institute of Hematology and Transfusiology, Tbilisi, 0177, Georgia|Medizinische Klinik und Poliklinik II der Charite Campus Mitte, Berlin, 10117, Germany|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, D-01307, Germany|Universitatsklinikum Freiburg Medizinische Klinik und Poliklinik, Freiburg, D-79106, Germany|Ernst-Moritz-Arndt-Universität Greifswald, Greifswald, 17487, Germany|Universitaetsklinikum Heidelberg Medizinische Klinik und Poliklinik V, Heidelberg, 69120, Germany|Medizinische Klinik und Poliklinik II, Leipzig, D-04103, Germany|Poliklinik A, Münster, 47589, Germany|Medizinische Klinik - Abteilung II, Tübingen, 72076, Germany|Medizinische Universitatsklinik, Ulm, 89081, Germany|Medizinische Klinik und Poliklinik II des Universitatsklinikums Wurzburg, Würzburg, 97080, Germany|G. GENNIMATAS General Hospital of Athens Department of Hematolgosy, Athens, 115 27, Greece|General Air Force Hospital, Athens, 11525, Greece|Alexandra General Hospital of Athens, Athens, 11528, Greece|Hope Directorate Haematology Oncology Service St. James Hospital, Dublin, 8, Ireland|Midlands Regional, Tullamore / Co Offally, Ireland|Rambam Medical Center, Haifa, 31096, Israel|Hadassah University Hospital, Jerusalem, 91120, Israel|Hematology Institute, Hemato-Oncology Division,Davidoff Cancer Center, Rabin MC Beilinson Hospital, Petch Tikva, 49100, Israel|The Chaim Sheba Medical Center, Tel Hashomer, 52621, Israel|Policlinico S. Orsola, Bologna, 40138, Italy|A.O.U. San Martino, Genova, 16132, Italy|Dipartmento Oncologico Struttura Complessa di ematlologiaA.O. Ospedale Niguarda Ca Granda, Milano, 20162, Italy|Policlinico San Matteo Universita Di Pavia, Pavia 2, 27100, Italy|Divisione Di Ematologia Ospedale Cattedra di Ematologia, Rome, 00144, Italy|Azienda Policlinico Umberto I, Universita La Sapienzadi Roma, Rome, 00161, Italy|Dipartimento di Onco-Ematologia, San Giovanni Rotondo (FG), 71013, Italy|Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista, Turin, 10126, Italy|VU Medical Center, Amsterdam, 1081 HV, Netherlands|Erasmus Medical Center, Rotterdam, 3015 GD/3000 CA, Netherlands|Erasmus Medisch Centrum, Rotterdam, 3015 GD, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Klinika Hematologii Samodzielny Publiczny Szpital Kliniczny Akademii, Bialystok, 15-276, Poland|Institute of Internal Diseases University of Medicine, Gdansk, 80-211, Poland|Oddzial Kliniczny Kliniki Hematologii, Krakow, 31-501, Poland|Uniwersytet Medyczny w Lodzi, Lodz, 93-509, Poland|University School of Medicine, Lublin, 20-290, Poland|Akademia Medyczna w Warszawie Samodzielny Publiczny Centralny Szpital Kliniczny, Warsaw, 02-097, Poland|Burdenko Central Military Clinical Hospital, Moscow, 105229, Russian Federation|Institution of Russian Academy of Medical Sciences Russian Oncological Research Centre n.a. N. N. Bl, Moscow, 115678, Russian Federation|Moscow Regional Research Institute n.a. Vladimirsky, Moscow, 129110, Russian Federation|Novosibirsk State Regional Clinical Hospital, Novosibirsk, 630087, Russian Federation|Medical Radiological Research Center RAMS, Obninsk, 249036, Russian Federation|Samara Regional Clinical Hospital, Samara, 443095, Russian Federation|St. Petersburg Research Institute of Hematology and Blood Transfusion, St. Petersburg, 191024, Russian Federation|Hospital Clinic, Barcelona, 08036, Spain|Hospital Universitaro Puerta del MarServicio de Hematologia, Cadiz, 11009, Spain|Hospital Universitario de la Princessa, Madrid, 28006, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Virgen del Rocio Servicio de Hematologia, Sevilla, 41013, Spain|Medicinkliniken, Boras, 501 82, Sweden|Medicinska kliniken, Malmö, 20502, Sweden|UniversitatsSpital ZurichKlinik fur Onkologie, Zurich, CH-8091, Switzerland|Ankara University, Ankara, 06620, Turkey|Marmara School of Medicine, Istanbul, 34662, Turkey|Ege University Medical School, Izmir, 35100, Turkey|Cherkassy Regional Oncology Center, Cherkassy, 18009, Ukraine|Dnepropetrovsk City Clinical Hospital 4, Dnepropetrovsk, 49044, Ukraine|Institute of Urgent and Recovery Surgery, Donetsk, 83047, Ukraine|Institute of Hematology and Transfusiology of the UAMS Department of blood diseases, Kiev, 04060, Ukraine|Institute of Blood Pathology and Transfusion Medicine of the AMS of Ukraine, Lviv 79044, Ukraine|Zhitomir Regional Clinical Hospital, Zhitomir, 10003, Ukraine|Monklands Hospital, Aidrie, ML6 0JS, United Kingdom|St James's University Hospital, Leeds, LS7 9TF, United Kingdom|University College London Hospitals Cancer Clinical Trials Unitist FloorCentral wing, London, NW1 2PG, United Kingdom|Kings College Hospital, London, SE5 9RS, United Kingdom|Christie NHS Trust Hospital, Manchester, M20 4BX, United Kingdom",
